Sodium Valproate + Valproic Acid (Valparin XR 500) should not be used in female children, in women of childbearing potential and in pregnant women unless other treatments are ineffective or not tolerated. Women of childbearing potential have to use effective contraception during treatment. In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible. Valproate is excreted in human milk with a concentration between 1% and 10% of maternal serum level, up to now children breastfed. A decision must be made whether to discontinue breast-feeding or to discontinue /abstain from valproate therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Sign Out
